Actavis Hits New 1-Year High at $191.71 (ACT)
Actavis (NYSE:ACT)’s share price reached a new 52-week high during mid-day trading on Tuesday , Stock Ratings News reports. The stock traded as high as $191.71 and last traded at $190.95, with a volume of 1,189,293 shares changing hands. The stock had previously closed at $188.76.
A number of research firms have recently commented on ACT. Analysts at Zacks upgraded shares of Actavis from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 4th. They now have a $224.00 price target on the stock. Separately, analysts at Morgan Stanley raised their price target on shares of Actavis from $182.00 to $205.00 in a research note on Monday, February 3rd. Finally, analysts at RBC Capital raised their price target on shares of Actavis from $202.00 to $222.00 in a research note on Monday, February 3rd. They now have an “outperform” rating on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $177.89.
The stock’s 50-day moving average is $177.9 and its 200-day moving average is $154.2. The company’s market cap is $33.278 billion.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.